Current Status and Perspectives in Cancer Chemotherapy.

Area of Science:

• Oncology
• Pharmacology
• Clinical Trials

Background:

• Novel anticancer drugs including paclitaxel, docetaxel, irinotecan, and gemcitabine demonstrate significant activity in solid tumors.
• Combination regimens and analogues of these drugs are under investigation in Phase II trials.
• Emerging therapies such as marine-derived compounds (ET-743), oral chemotherapy (UFT, capecitabine), and monoclonal antibodies (17-1A, HUM195) are being evaluated.

Purpose of the Study:

• To review recent advancements in anticancer drug development and clinical trials.
• To highlight the efficacy of novel drug combinations and targeted therapies.
• To discuss the potential of new therapeutic strategies, including oral chemotherapy and antibody-based treatments.

Main Methods:

• Review of Phase II clinical trial data for new anticancer agents and combination regimens.
• Evaluation of novel drug classes, including marine products, oral chemotherapeutics, and monoclonal antibodies.
• Discussion of emerging therapeutic targets such as angiogenesis inhibitors.

Main Results:

• Paclitaxel plus cisplatin combination shows superiority in ovarian cancer compared to standard regimens.
• Oral capecitabine demonstrates superior activity and reduced toxicity versus 5-fluorouracil/leucovorin in colorectal cancer.
• Monoclonal antibody therapy has shown success in HER2-positive breast cancer and B-cell lymphoma; ongoing trials for colorectal cancer and acute myelogenous leukemia.

Conclusions:

• Novel anticancer drugs and therapeutic strategies are expanding treatment options for various cancers.
• Combination therapies and targeted agents, including monoclonal antibodies and oral chemotherapeutics, offer improved efficacy and reduced toxicity.
• Continued research and clinical trials are crucial for developing more effective cancer treatments.